Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) from a hold rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. Guggenheim upped their target price on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Down 2.1%

Shares of NASDAQ DMRA opened at $20.22 on Friday. The stock’s 50-day simple moving average is $27.24 and its two-hundred day simple moving average is $25.99. Damora Therapeutics, Inc. Common Stock has a twelve month low of $3.64 and a twelve month high of $38.33. The firm has a market capitalization of $1.25 billion, a P/E ratio of -6.00 and a beta of 1.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. As a group, research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction on Friday, September 25th. The stock was acquired at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the purchase, the chief executive officer directly owned 512,500 shares in the company, valued at $10,367,875. This represents a 2.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors and hedge funds have recently made changes to their positions in the business. Braidwell LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth about $42,146,000. Seven Fleet Capital Management LP purchased a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth approximately $7,398,000. Squarepoint Ops LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $303,000. Finally, Arizona State Retirement System bought a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $260,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.